Back to Search Start Over

Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review

Authors :
Bai Jiwei
Muyasha Abulimiti
Jin Yonglong
Wang Jie
Zhang Shuyan
Liu Chao
Wang Zishen
Wang Wei
Li Yinuo
Wang Weiwei
Yang Lu
Shosei Shimizu
Source :
Radiation Oncology, Vol 19, Iss 1, Pp 1-8 (2024)
Publication Year :
2024
Publisher :
BMC, 2024.

Abstract

Abstract Objective This report details the experience of a patient who developed a second primary glioblastoma (GB), offering insights into the treatment process and reviewing relevant literature. Case presentation A male patient, who was diagnosed with medulloblastoma at age 9, received treatment with cobalt-60 craniospinal irradiation (CSI) (36 Gy/20 fractions) and a tumor bed boost (total of 56 Gy). After 32 years, at age 41, an MRI revealed a space-occupying mass in the left cerebellar hemisphere. Surgical resection was performed, and postoperative pathology confirmed a diagnosis of radiation-induced glioblastoma (RIGB). Given the history of irradiation and the current tolerability of brainstem doses, proton beam therapy (PBT) combined with Temozolomide (75 mg/m2) was chosen. The treatment plan included 60 Gy on the gross tumor bed and 54 Gy on the clinical target volume, delivered in 30 fractions. The patient underwent regular follow-up and achieved a complete response. Clinical discussion For childhood cancer survivors, the development of a second primary tumor significantly impacts prognosis. RIGB is a rare form of secondary tumor with distinct molecular characteristics compared to primary GB and recurrent secondary GB. Molecular markers such as IDH and MGMT status can help differentiate between primary GB, recurrent secondary GB, and radiation-induced secondary GB in patients with a history of prior radiation therapy. Surgical resection remains a primary treatment option, while PBT is preferred for postoperative treatment due to its superior protection of normal tissues and the ability to deliver high-dose irradiation. Conclusion RIGB is a rare second primary tumor that requires strategic molecular profiling and individualized management. Proton beam therapy provides effective high-dose irradiation in the postoperative phase and is the preferred treatment option for such cases.

Details

Language :
English
ISSN :
1748717X
Volume :
19
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Radiation Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.309a10e0fe7e42fea930945777a8f8d3
Document Type :
article
Full Text :
https://doi.org/10.1186/s13014-024-02515-5